about
DNA and protein co-immunization improves the magnitude and longevity of humoral immune responses in macaquesImmunogenicity of novel consensus-based DNA vaccines against Chikungunya virusIn vivo protection against ZIKV infection and pathogenesis through passive antibody transfer and active immunisation with a prMEnv DNA vaccine.MESOMARK: a potential test for malignant pleural mesotheliomaIntramuscular delivery of heterodimeric IL-15 DNA in macaques produces systemic levels of bioactive cytokine inducing proliferation of NK and T cellsLong-term programming of antigen-specific immunity from gene expression signatures in the PBMC of rhesus macaques immunized with an SIV DNA vaccineProtective immunity to H7N9 influenza viruses elicited by synthetic DNA vaccine.An Enhanced Synthetic Multiclade DNA Prime Induces Improved Cross-Clade-Reactive Functional Antibodies when Combined with an Adjuvanted Protein Boost in Nonhuman Primates.Prototype development and preclinical immunogenicity analysis of a novel minimally invasive electroporation device.DNA vaccination protects mice against Zika virus-induced damage to the testesA human immune data-informed vaccine concept elicits strong and broad T-cell specificities associated with HIV-1 control in mice and macaques.Altered response hierarchy and increased T-cell breadth upon HIV-1 conserved element DNA vaccination in macaques.Functional analysis of peptide motif for RNA microhelix binding suggests new family of RNA-binding domainsImmunogenicity of a novel engineered HIV-1 clade C synthetic consensus-based envelope DNA vaccine.Optimization of electroporation-enhanced intradermal delivery of DNA vaccine using a minimally invasive surface device.Highly optimized DNA vaccine targeting human telomerase reverse transcriptase stimulates potent antitumor immunity.Humoral immunity induced by mucosal and/or systemic SIV-specific vaccine platforms suggests novel combinatorial approaches for enhancing responses.An optimized, synthetic DNA vaccine encoding the toxin A and toxin B receptor binding domains of Clostridium difficile induces protective antibody responses in vivoStrong HCV NS3/4a, NS4b, NS5a, NS5b-specific cellular immune responses induced in Rhesus macaques by a novel HCV genotype 1a/1b consensus DNA vaccine.HIV-1 p24(gag) derived conserved element DNA vaccine increases the breadth of immune response in mice.Direct transfection of dendritic cells in the epidermis after plasmid delivery enhanced by surface electroporation.Activated CD4+CCR5+ T cells in the rectum predict increased SIV acquisition in SIVGag/Tat-vaccinated rhesus macaques.Comparison of immune responses generated by optimized DNA vaccination against SIV antigens in mice and macaquesHIV-1 Env DNA vaccine plus protein boost delivered by EP expands B- and T-cell responses and neutralizing phenotype in vivoSynthetic consensus HIV-1 DNA induces potent cellular immune responses and synthesis of granzyme B, perforin in HIV infected individualsA highly optimized DNA vaccine confers complete protective immunity against high-dose lethal lymphocytic choriomeningitis virus challenge.Hepatitis C virus NS3/NS4A DNA vaccine induces multiepitope T cell responses in rhesus macaques mimicking human immune responses [corrected]Optimized in vivo transfer of small interfering RNA targeting dermal tissue using in vivo surface electroporation.A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates.Induction of robust cellular immunity against HPV6 and HPV11 in mice by DNA vaccine encoding for E6/E7 antigen.Intradermal DNA vaccination enhanced by low-current electroporation improves antigen expression and induces robust cellular and humoral immune responses.Novel synthetic plasmid and Doggybone DNA vaccines induce neutralizing antibodies and provide protection from lethal influenza challenge in miceDNA vaccines targeting heavy chain C-terminal fragments of Clostridium botulinum neurotoxin serotypes A, B, and E induce potent humoral and cellular immunity and provide protection from lethal toxin challengeDose-dependent inhibition of Gag cellular immunity by Env in SIV/HIV DNA vaccinated macaquesImmunogenicity of a novel enhanced consensus DNA vaccine encoding the leptospiral protein LipL45Chemokine-adjuvanted electroporated DNA vaccine induces substantial protection from simian immunodeficiency virus vaginal challengeDNA and virus particle vaccination protects against acquisition and confers control of viremia upon heterologous simian immunodeficiency virus challengeThe p40 subunit of interleukin (IL)-12 promotes stabilization and export of the p35 subunit: implications for improved IL-12 cytokine production.IL-12 DNA as molecular vaccine adjuvant increases the cytotoxic T cell responses and breadth of humoral immune responses in SIV DNA vaccinated macaquesVaccination with synthetic constructs expressing cytomegalovirus immunogens is highly T cell immunogenic in mice.
P50
Q27316075-07E41F3C-74D9-421C-B6F9-4AB069D9F249Q27487330-650C190F-AD7E-4641-94BC-1EB03A6A097CQ27901935-22F191F1-0719-4E9C-8A34-8619E5458ED0Q28287442-E0680942-3C08-4330-8589-4A4A7376D7A5Q28652428-A4270194-7280-4A63-BEFB-C44BAA63D67CQ28743435-08C3D113-B915-4EE3-B20A-BE7EC8C8256CQ30360232-2227A05C-C410-4F8C-960F-F181B53E74E3Q30375785-517E3FD3-D55A-4B51-A0D5-B62766AFFC36Q30395101-10D5D238-F19F-49F6-BEFD-F5A3F78A8717Q30855414-279244C3-F4E7-4E3F-A22F-2297CE9B4527Q30934059-6106F8D7-7415-4923-A9F7-E966F898DC2CQ31148797-ECB3933B-0F0F-4456-ACF1-771BF5699E9BQ32022036-C112E5F8-6E78-43B1-AE0A-7E0F6573483BQ33576984-31D81573-033B-4C1C-80F8-09CC44AA8399Q33586294-DA60EED8-2AD9-4531-8095-7FE6456FD7F0Q33897405-CE80A3FA-041B-4D40-BF15-936ABAD56285Q33915690-C67CD21A-DEAC-48CB-8F21-460C280663DEQ34298763-72315CA6-A51B-45CD-8762-3750FEBC00D8Q34449537-7FBD430B-8C2E-484B-92F0-32967BB11AF8Q34653619-A0CF6363-BF8F-41A6-877C-4A5208B89425Q34719492-AD3B2DAE-D343-4231-BB9E-9DE1CFD0FFCFQ34985353-D937D599-F2DD-4ACF-9A71-F1F340843A54Q35046349-896B9445-3138-4AD3-8C40-F606A0E3F27AQ35082880-1DE8EFE3-71D4-4439-9D3D-94FB838F4D78Q35153129-09D6E600-DCF1-46F3-90E3-40201D83F0EAQ35196530-FDBBB6C5-44DB-4988-8DF4-3105A52D8B4FQ35802129-3880BFE7-D10C-4C07-B359-12767627F4ABQ36053828-77555CA8-04CF-4FA5-A28D-F39D8926A6EFQ36069589-A90858EA-A9BE-4D41-92B5-EDBDC26934B4Q36184362-30626CB6-5326-4D74-991D-22BA197DA9ECQ36228884-67E5D494-ABFE-42A0-9F50-B4B8247144DFQ36255758-09FC58C2-E113-46AA-BF2C-CB466B624D9DQ36256249-1FF4C971-324E-4CC6-BB4F-4D0BF9715780Q36256319-93059076-EE8C-43EF-9362-B783FA0A1F3CQ36256428-69091E1A-2076-481E-B255-9F0E73C36A40Q36258203-C943E7A4-2399-4732-A04D-F4D1BF333796Q36637349-FB1D24D4-5ED4-4EDB-94C5-CB30DB6ED56DQ36647429-AB79A7BF-B676-46F3-AEA1-69FB15C4E188Q36694836-29D3AB6D-D243-4411-83E7-622412F45232Q36694861-BA4D9E66-0AB0-4A9C-93E6-5E88041B9A0C
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0001-6920-1167
@en
name
Niranjan Y Sardesai
@ast
Niranjan Y Sardesai
@en
Niranjan Y Sardesai
@es
Niranjan Y Sardesai
@nl
type
label
Niranjan Y Sardesai
@ast
Niranjan Y Sardesai
@en
Niranjan Y Sardesai
@es
Niranjan Y Sardesai
@nl
prefLabel
Niranjan Y Sardesai
@ast
Niranjan Y Sardesai
@en
Niranjan Y Sardesai
@es
Niranjan Y Sardesai
@nl
P106
P1153
26434829400
P31
P496
0000-0001-6920-1167